U.S. Markets open in 7 hrs 5 mins

Myriad Genetics, Inc. (MYGN)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
26.255-0.22 (-0.81%)
At close: 4:00PM EDT
People also watch
PDLIINCYVRTXNBIXALKS

Myriad Genetics, Inc.

320 Wakara Way
Salt Lake City, UT 84108
United States
801-584-3600
http://www.myriad.com

SectorServices
IndustryResearch Services
Full Time Employees2,206

Key Executives

NameTitlePayExercisedAge
Mr. Mark Christopher CaponeChief Exec. Officer, Pres and Director1.54MN/A55
Mr. R. Bryan RiggsbeeChief Financial Officer, Exec. VP and Treasurer590.53kN/A46
Dr. Jerry S. Lanchbury Ph.D.Chief Scientific Officer706.94k2.95M58
Mr. Richard M. Marsh Esq.Exec. VP, Gen. Counsel and Sec.708.87k1.48M59
Mr. Bernard F. TobinPres of Crescendo Bioscience Inc615.52kN/A60
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Myriad Genetics, Inc., a personalized medicine company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It operates through two segments, Diagnostics and Other. The Diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease; identify a patient’s likelihood of responding to drug therapy; guide a patient’s dosing to ensure optimal treatment; and assess a patient’s risk of disease progression and disease recurrence. The Other segment provides testing products and services to the pharmaceutical, biotechnology, and medical research industries; and research and development, and clinical services for patients. Its molecular diagnostic DNA sequencing tests include myRisk Hereditary cancer, a test for hereditary cancers; BRACAnalysis and BART, which are tests for hereditary breast and ovarian cancers; BRACAnalysis CDx test for use in identifying ovarian cancer patients with suspected deleterious germline; and Tumor BRACAnalysis CDx test that is used to predict DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors. The company also provides COLARIS test for colorectal and uterine cancers; COLARIS AP test for colorectal cancer; Vectra DA protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for prostate cancer; EndoPredict RNA expression test for breast cancer; myPath Melanoma RNA expression test for diagnosing melanoma; myChoice homologous recombination deficiency (HRD) test to measure three modes of HRD; and myPlan lung cancer, an RNA expression test for lung cancer. Myriad Genetics, Inc. has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Corporate Governance

Myriad Genetics, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.